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Abstract
Background:Breast cancer in younger patients is reported to
be more aggressive and associated with lower survival; how-
ever, factors associated with age-specific mortality differences
have not been adequately assessed.
Methods: We used data from the population-based
California Cancer Registry for 38,509 younger (18–49 years)
and 121,573 older (50 years and older) women diagnosed
with stage I to III breast cancer, 2005–2014.Multivariable Cox
regressionmodels were used to estimate breast cancer–specific
mortality rate ratios (MRR) and 95%confidence intervals (CI),
stratifiedby tumor subtype, guideline treatment, and care at an
NCI-designated cancer center (NCICC).
Results: Older breast cancer patients at diagnosis experi-
enced 17% higher disease-specific mortality than younger
patients, after multivariable adjustment (MRR ¼ 1.17; 95%
CI, 1.11–1.23). Higher MRRs (95% CI) were observed for
older versus younger patients with hormone receptor
(HR)þ/HER2– (1.24; 1.14–1.35) and HRþ/HER2þ (1.38;
1.17–1.62), but not for HR–/HER2þ (HR ¼ 0.94; 0.79–1.12)
nor triple-negative breast cancers (1.01; 0.92–1.11).
The higher mortality in older versus younger patients was
diminished among patients who received guideline-concor-
dant treatment (MRR ¼ 1.06; 95% CI, 0.99–1.14) and
reversed among those seen at an NCICC (MRR ¼ 0.86;
95% CI, 0.73–1.01).
Conclusions: Although younger women tend to be diag-
nosed with more aggressive breast cancers, adjusting for these
aggressive features results in older patients having higher
mortality than younger patients, with variations by age, tumor
subtype, receipt of guideline treatment, and being cared for at
an NCICC.
Impact: Higher breast cancer mortality in older compared
with younger women could partly be addressed by ensuring
optimal treatment and comprehensive patient-centered care.
Introduction
Breast cancer is the most common cancer among women
worldwide, accounting for a fifth of overall cancer mortality
(1). In the United States, less than 20% of all breast cancer cases
occur before the age of 50 years (2). Results of some studies have
shown that younger compared with older breast cancer patients
have poorer survival, with studies focusing on age groups less than
40 years (3–5). For breast cancer mortality endpoints, two studies
based on the Surveillance, Epidemiology, and End Results (SEER)
Program reported that younger comparedwith older breast cancer
patients had higher breast cancer mortality, with HRs of 1.095
[95% confidence interval (CI), 1.101–1.183] comparing patients
less than 35 with those 50 to 55 years of age in one study (6) and
1.39 (CI, 1.34 to 1.45) in the second study comparingwomen <40
with those 40þ years of age (7). Variations in estimates of risk
could be due to the inconsistent use of referent and comparison
age groups and to covariates included in multivariate models.
Proposed reasons for higher mortality in younger versus older
patients include later stage disease, more aggressive tumors, and
less favorable tumor receptor status in younger thanolder patients
(5, 6). However, biological, undertreatment, and socioeconomic
status (SES) factors may potentially result in higher mortality
among older compared with younger patients (8–11).
To our knowledge, there are no published reports regarding
differences in breast cancermortality for the age cut off of 50 years,
a marker for menopausal status and for recommended initiation
of screening mammography (12, 13). Furthermore, although
breast cancer survival has been shown to vary according to tumor
subtype (14), comparison of prognostic factors between younger
and older patients by tumor subtype is poorly understood,
especially in population-based settings.
Using data from the population-based California Cancer Reg-
istry (CCR), our study takes advantage of the completeness of
tumor subtype information in the registry in the mid-2000s to
assess breast cancer mortality differences between breast cancer
patients who were younger (age 18–49) and older (age 50
and above) at diagnosis. We further assessed the moderating
effects of tumor biology and clinical factors by examiningwhether
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mortality differences vary by tumor subtype, receiving guideline-




We obtained from CCR information about all female
California residents age 18 years and older at diagnosis who
were diagnosed with a first, primary invasive breast cancer
[International Classification of Disease for Oncology, 3rd
Edition, (ICD-O-3) site codes C50.0–50.9] during January 1,
2005, through December 31, 2014 (n ¼ 196,628). As the criteria
for guideline treatment were limited to patients diagnosed with
American Joint Committee on Cancer (AJCC) stage I to III breast
cancer, our analysis did not include patients with stage unknown
or stage IV breast cancer (n ¼ 19,842). Patients were additionally
excluded from analysis hierarchically as follows: diagnosis by
death certificate or autopsy only (n ¼ 19) or diagnosis not
microscopically confirmed (n ¼ 187); ICD-O-3 histologic type
other than 8000, 8001, 8010, 8020, 8022, 8050, 8140, 8201,
8211, 8230, 8255, 8260, 8401, 8453, 8480, 8481, 8500–8525,
or 8575 (n ¼ 2,217); tumor size missing because unknown
(n ¼ 667), no tumor noted (n ¼ 236), microscopic (n ¼ 2,009),
diffuse (n ¼ 280), or mammographic diagnosis only (n ¼ 54);
young patient insured by Medicare (n ¼ 403); no follow-up
(n ¼ 210); second primary breast tumor diagnosed within
60 days of initial tumor (n ¼ 5,068); bilateral tumors at initial
diagnosis (n ¼ 7); residential address that was uncertain or
not geocodable (n ¼ 5,347). Analyses thereby included
160,082 patients, of which 38,509 were younger (age 18–
49) and 121,573 were older (age 50 and above, up to age
103) patients.
We obtained information from the CCR, which is derived from
the patient's medical record, on age at diagnosis, race/ethnicity
(non-Hispanic white, non-Hispanic black, Hispanic, Asian/
Pacific Islander, or other/unknown), marital status, residential
address at diagnosis, stage at diagnosis, tumor size (in cm), lymph
node involvement, histology, grade (I, II, III/IV, or unknown),
primary source of payment (private only, any Medicaid/military/
Other public, Medicare only/Medicare þ private, no insurance,
and unknown), hormone receptor [estrogen receptor (ER)
and progesterone receptor (PR) together referred as hormone
receptor (HR), and HER2] status, as well as initial treatment
modalities [surgery, radiotherapy, and chemotherapy (endo-
crine therapy is undercaptured in cancer registry data)]. We
followed patients for vital status from linkage with vital records
as of December 31, 2014.
We used a multicomponent measure of neighborhood SES
(nSES), based on patients' residential census block group at
diagnosis. This measure incorporated the 2000 U.S. Census (for
cases diagnosed in 2005) and the 2006–2010 American Com-
munity Survey data (for cases diagnosed in 2006 and forward) on
education, occupation, unemployment, household income, pov-
erty, rent, and house values (15, 16). Each patient was assigned an
nSES quintile, based on the distribution of SES across census
block groups in California.
Breast cancer tumor subtype definition
We used the breast cancer subtype definition as previously
defined (17). Briefly, the CCR has collected information on the
expression of ER and PR since 1990 and of HER2 since 1999 (18),
with HER2 data completeness increasing greatly after 2005. We
classified breast cancers into four mutually exclusive subtype
categories: HRþ/HER2– (defined as ER and/or PR positive and
HER2 negative), HRþ/HER2þ (ER and/or PR positive and HER2
positive), HR–/HER2þ (ER and PR negative and HER2 positive),
and triple-negative breast cancer (TNBC, ER, PR, and HER2
negative; refs. 14, 18–21). Of the 160,082 cancers in this analysis,
16,373 (10.2%)did not have information needed to assign to one
of these subtypes, including 11,012 cancers (6.9%) for whom
only HER2 status was unknown, 631 cancers (0.4%) for whom
onlyHR statuswasunknown, and4,730 cancers (3.0%) forwhom
both HR and HER2 statuses were unknown.
Guideline treatment and receipt of care
Receipt of guideline-concordant care was based on whether
women reported receiving treatment that aligned with the
National Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology (22) and the American Society
of Clinical Oncology Quality Oncology Practice Initiative
(23, 24). Cancer registry first course of treatment data on receipt
of surgery (lumpectomy, mastectomy, axillary, or sentinel node
dissection), radiotherapy, and/or chemotherapy were obtained.
Each woman was considered to be in one or more patient
subsets based on her age and tumor characteristics (subtype,
lymph node involvement, and tumor size). Women with any
nonconcordant care were categorized as not receiving guideline
treatment. As described in a prior SEER study (25), the subsets
were used to define appropriate treatment options (Table 1).
Women who did not fall into either subset were classified in
regard to guideline concordant treatment as "Not applicable,"
and those who were in one or more subset but were missing the
treatment data needed to determine concordance were classi-
fied as "Unknown."
Receiving care at an NCICC was based on diagnosis and/or
treatment occurring at such centers. In a population-based setting,
because patients may be seen and have received care at multiple
facilities, and also due to how the CCR data onmultiple reporting
facilities are coded, it is not possible to determine the treating
facilities.
Statistical analysis
Follow-up time was calculated as the number of days
between the date of diagnosis and the earliest of: the date of
death from breast cancer (ICD 9/10 ¼ 174/C50), the date of
death from another cause, the date of last follow-up (i.e., last
known contact), or the study end date (December 31, 2014).
The 545 deceased patients with an unknown cause of death
were excluded from all models. Cox proportional hazards
regression was used to estimate the breast cancer–specific
mortality rate ratio (MRR) and corresponding associated
95% CIs for the two age groups with fully adjusted models
adjusted for year of diagnosis (continuous), marital status,
race/ethnicity, insurance status, nSES, lymph nodes involve-
ment, tumor subtype, tumor size, tumor grade, tumor histol-
ogy, receipt of guideline concordant treatment, and whether the
patient was seen at one or more of the NCICC in California for
her breast cancer. Fully adjusted models were additionally
adjusted for clustering by block group, using a sandwich
estimator of the covariance structure that accounts for intraclus-
ter dependence. The proportional hazards assumption was
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examined by statistical testing of the correlation between
weighted Schoenfeld residuals and logarithmically transformed
survival time. No violations of the assumption were observed,
except for AJCC stage at diagnosis. Thus, stage was included as
an underlying stratifying variable in the fully adjusted Cox
regression models, allowing the baseline hazard to vary by
stage. Wald Type 3 tests for interaction between age group
(18–49, 50þ) and tumor subtype, NCICC, or guideline con-
cordant treatment (excluding Unknown) were computed using
cross-product terms, in models adjusted for all statistically
significant (P < 0.05) interactions with age group (year, insur-
ance status, tumor subtype, NCICC, and guideline concordant
treatment). All statistical tests were carried out using SAS
software version 9.3 (SAS Institute).
Results
In this population-based study in California (n ¼ 160,082),
38,509 (24.1%) female patients under the age 50 years at
diagnosis presented with stage I to III breast cancer; 121,573
(75.9%) were aged 50 and above. As shown in Table 2,
compared with older patients, younger women were more
likely to be Hispanic (27% vs. 16%), be married (64% vs.
54%), be covered by private insurance only (76% vs. 54%),
have TNBC (13% vs. 10%), be diagnosed with tumors over 2
cm in size (49% vs. 36%), and have ductal tumors (83% vs.
78%). Younger patients were less likely to be diagnosed with
stage I cancer (39% vs. 54%), grade I tumors (16% vs. 25%),
and negative lymph node involvement (58% vs. 71%) than
older patients. No substantial differences were shown for nSES,
NCICC status, or guideline concordant treatment between
younger and older patients.
Multivariable-adjusted risk of breast cancer mortality for
older versus younger patients categorized by 10-year age groups
shows that compared with patients ages 40 to 49 years, a
progressively higher risk of mortality is shown for older age
groups with the highest risk shown in women 80 years and
older (MRR ¼ 3.25; 95% CI, 2.98–3.55; Table 3). Results using
an age cutoff at 50 years show that older patients had a higher
risk of mortality than younger patients (MRR ¼ 1.17; 95% CI,
1.11–1.23).
Breast cancer mortality according to tumor subtype, guideline-
appropriate treatment, and receiving care at an NCICC, stratified
by age group, is presented in Table 4. Significant interactions
between age group and tumor subtype (P ¼ 0.0008), NCICC
(P ¼ 0.003), and guideline-appropriate treatment (P ¼ 0.015)
wereobserved.Among youngerwomen, patientswithHRþ/HER2þ
disease had a lower risk of dying (MRR¼ 0.80; 95%CI, 0.69–0.93)
than those with HRþ/HER2– tumors, whereas a higher risk was
shown for patientswithHR–/HER2þ tumors (MRR¼ 1.37; 95%CI,
1.15–1.62) and those with TNBC (MRR ¼ 2.50; 95% CI, 2.19–
2.86). In older patients, higher mortality was observed for patients
with HR–/HER2þ (MRR ¼ 1.28; 95% CI, 1.14–1.43) and TNBC
(MRR¼ 2.35; 95%CI, 2.17–2.53) but not forHRþ/HER2þ tumors
(MRR ¼ 1.05; 95% CI, 0.95–1.15) when compared with women
with HRþ/HER2–. Older women who received care at an NCICC
had a lower risk of dying frombreast cancer than thosewhodid not
(MRR ¼ 0.84; 95% CI, 0.76–0.93); no difference was seen in
younger patients (MRR ¼ 1.00; 95% CI, 0.89–1.13). In both
younger (MRR ¼ 1.20; 95% CI, 1.03–1.40) and older patients
(MRR¼1.49;95%CI,1.36–1.63), a higher risk ofdyingwas shown
for women who did not receive guideline-appropriate treatment,
compared with those who did.
Table 5 shows the multivariable-adjusted breast cancer MRRs
for older comparedwith younger patients. Stratifiedmultivariable
analyses by tumor subtype showed higher mortality for
older compared with younger patients who were diagnosed with
HRþ/HER2– (MRR ¼ 1.24; 95% CI, 1.14–1.35) and with
HRþ/HER2þ tumors (MRR ¼ 1.38; 95% CI, 1.17–1.62) but not
for those with HR–/HER2þ (MRR ¼ 0.94; 95% CI, 0.79–1.12) or
TNBC (MRR¼ 1.01; 95%CI, 0.92–1.11).Olderwomenwhowere
not cared for at anNCICC had a higher risk of dying than younger
patients (MRR ¼ 1.21; 95% CI, 1.15–1.28), but the opposite was
seen amongwomen cared for at anNCICC (MRR¼ 0.86, 95%CI,
0.73–1.01). Older as compared with younger patients who did
not receive guideline-appropriate treatment had a higher risk of
dying (MRR ¼ 1.20; 95% CI, 1.02–1.41) but those who had
guideline-concordant treatment were not at higher risk (MRR ¼
1.06; 95% CI, 0.99–1.14).
Discussion
In this large and representative series of women diagnosedwith
invasive stage I to III breast cancer in California, we found that
after taking into account clinical and sociodemographic factors,
older patients at diagnosis experience 17% higher breast cancer
mortality than younger patients. However, variation in risk was
shown according to tumor subtype, receipt of care at an NCICC,
Table 1. Criteria for determination of receipt of non–guideline-concordant care
Subset Inclusion criteria Guideline treatment
Definition of non–guideline-
concordant treatment
1 & Stage I–III & Lumpectomy with full course of
radiotherapy
& No surgery
& Tumor size  5 cm & Lumpectomy without radiotherapy
& Not having a diagnosis of Paget disease or
inflammatory carcinoma
& Lumpectomy with early discontinuation of
radiotherapy
& Confirmed pathology & Mastectomy, with or without
radiotherapy& Known lymph node involvement
& Tumor not bilateral
& No diagnosis of a second primary breast
tumor within 60 days
2 & Stage I–III & Chemotherapy & No chemotherapy
& Age < 70
& ER– and PR–
& Tumor size  1 cm
& Confirmed pathology
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Table 2. Patient demographic and clinical characteristics for younger (18–49 years) and older (50þ years) age at breast cancer diagnosis, California, 2005–2014
All Younger (18–49) Older (50þ)
Total number of patients 160,082 (100.0%) 38,509 (100.0%) 121,573 (100.0%)
Age (y), mean (SD) 60.1 (13.6) 42.8 (5.3) 65.6 (10.5)
Age category
18–39 8,822 (5.5%) 8,822 (22.9%)
40–49 26,687 (18.5%) 29,687 (77.1%)
50–59 40,840 (25.5%) 40,840 (33.6%)
60–69 40,163 (25.1%) 40,163 (33.0%)
70–79 25,849 (16.1%) 25,849 (21.3%)
80þ 14,721 (9.2%) 14,721 (12.1%)
Race/ethnicity
Non-Hispanic white 97,459 (60.9%) 18,275 (47.5%) 79,184 (65.1%)
Non-Hispanic black 9,831 (6.1%) 2,581 (6.7%) 7,250 (6.0%)
Hispanic 29,856 (18.7%) 10,502 (27.3%) 19,354 (15.9%)
Asian/Pacific Islander 21,159 (13.2%) 6,714 (17.4%) 14,445 (11.9%)
Other/unknown 1,777 (1.1%) 437 (1.1%) 1,340 (1.1%)
Marital status
Married 90,433 (56.5%) 24,717 (64.2%) 65,716 (54.1%)
Unmarried 63,794 (39.9%) 12,497 (32.5%) 51,297 (42.2%)
Unknown 5,855 (3.7%) 1,295 (3.4%) 4,560 (3.8%)
Neighborhood (block group) state-wide SES quintile
1st (lowest) 19,283 (12.0%) 5,041 (13.1%) 14,242 (11.7%)
2nd 27,202 (17.0%) 6,413 (16.7%) 20,789 (17.1%)
3rd 32,684 (20.4%) 7,497 (19.5%) 25,187 (20.7%)
4th 38,182 (23.9%) 9,109 (23.7%) 29,073 (23.9%)
5th (highest) 42,731 (26.7%) 10,449 (27.1%) 32,282 (26.6%)
Insurance status
Private only 94,291 (58.9%) 29,199 (75.8%) 65,092 (53.5%)
Any Medicaid/military/other public 26,350 (16.5%) 7,701 (20.0%) 18,649 (15.3%)
Medicare only or Medicare þ private 33,918 (21.2%) 33,918 (27.9%)
No insurance 1,259 (0.8%) 475 (1.2%) 784 (0.6%)
Unknown 4,264 (2.7%) 1,134 (2.9%) 3,130 (2.6%)
NCICC
No 143,322 (89.5%) 32,708 (84.9%) 110,614 (91.0%)
Yes 16,760 (10.5%) 5,801 (15.1%) 10,959 (9.0%)
AJCC stage
I 80,530 (50.3%) 15,002 (39.0%) 65,528 (53.9%)
II 59,779 (37.3%) 16,990 (44.1%) 42,789 (35.2%)
III 19,773 (12.4%) 6,517 (16.9%) 13,256 (10.9%)
Tumor subtype
HRþ/HER2– 103,807 (64.8%) 22,331 (58.0%) 81,476 (67.0%)
HRþ/HER2þ 15,893 (9.9%) 5,235 (13.6%) 10,658 (8.8%)
HR–/HER2þ 7,332 (4.6%) 2,138 (5.6%) 5,194 (4.3%)
Triple negative 16,677 (10.4%) 5,176 (13.4%) 11,501 (9.5%)
Unclassified 16,373 (10.2%) 3,629 (9.4%) 12,744 (10.5%)
Lymph node involvement
Negative 109,069 (68.1%) 22,478 (58.4%) 86,591 (71.2%)
Positive 50,925 (31.8%) 16,019 (41.6%) 34,906 (28.7%)
Unknown 88 (0.1%) 12 (0.0%) 76 (0.1%)
Tumor size (cm)
0.10 < tumor  0.50 11,782 (7.4%) 2,343 (6.1%) 9,439 (7.8%)
0.50 < tumor  1.00 27,166 (17.0%) 4,600 (11.9%) 22,566 (18.6%)
1.00 < tumor  2.00 58,110 (36.3%) 12,737 (33.1%) 45,373 (37.3%)
2.00 < tumor  5.00 52,235 (32.6%) 15,080 (39.2%) 37,155 (30.6%)
>5.00 10,789 (6.7%) 3,749 (9.7%) 7,040 (5.8%)
Grade
Grade I 36,815 (23.0%) 6,141 (15.9%) 30,674 (25.2%)
Grade II 67,075 (41.9%) 14,893 (38.7%) 52,182 (42.9%)
Grade III/IV 50,885 (31.8%) 16,167 (42.0%) 34,718 (28.6%)
Unknown 5,307 (3.3%) 1,308 (3.4%) 3,999 (3.3%)
Histology
Ductal 126,506 (79.0%) 32,068 (83.3%) 94,438 (77.7%)
Lobular 25,753 (16.1%) 4,805 (12.5%) 20,948 (17.2%)
Other 7,823 (4.9%) 1,636 (4.2%) 6,187 (5.1%)
Guideline-concordant treatment
Yes 47,057 (29.4%) 15,434 (40.1%) 31,623 (26.0%)
No 8,184 (5.1%) 2,306 (6.0%) 5,878 (4.8%)
Not applicable 104,530 (65.3%) 20,665 (53.7%) 83,865 (69.0%)
Unknown 311 (0.2%) 104 (0.3%) 207 (0.2%)
Tao et al.
Cancer Epidemiol Biomarkers Prev; 28(2) February 2019 Cancer Epidemiology, Biomarkers & Prevention306
on March 9, 2021. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst October 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0353 
and receiving guideline-concordant treatment. The difference in
breast cancer mortality between older and younger patients was
evident for patients with HRþ tumors regardless of HER2 status,
whereas no difference was observed for women with HR– disease
(HR–/HER2þ and TNBC). The higher mortality among older
versus younger women was diminished in patients receiving
guideline treatment and reversed among those seen at an NCICC,
suggesting that appropriate treatment improves survival among
older women. Although age differences regarding breast cancer
aggressiveness andmortality outcomes have beenpublished (6, 7,
26, 27), to our knowledge no comprehensive reports exist on
differences by age for associations between tumor subtype and
clinical prognostic factors and breast cancer mortality. In these
analyses, we were able to account for a number of sociodemo-
graphic and clinical factors as covariates, which provided a com-
prehensive assessment of age-specific differences in breast cancer
mortality.
Presence of aggressive breast tumor subtypes was higher in
younger than older women (19.2% HER2þ in younger vs. 13.1%
in older patients, and 13.4% TNBC in younger vs. 9.5% in older
patients), which is consistent with findings from other studies
(28–30). TNBC has been difficult to study before 2005, especially
in population settings, since routine HER2 testing for breast
cancers was not implemented at large until after Trastuzumab
was approved for the adjuvant treatment of early-stage breast
cancer in 2005.Comprising less than20%of breast cancers, TNBC
is associated with worse survival than other subtypes, in part due
to the lack of targeted therapeutic agents (30, 31). Our study
shows that patients diagnosed with TNBC have a greater than
2-fold increased risk of dying compared with those with
HRþ/HER2– breast cancer regardless of age group, underscoring
the aggressive nature of TNBC subtype.
Stratified analyses by age group showed that among younger
patients, patients with HRþ/HER2þ tumors had lower risk of
dying as compared with those with HRþ/HER2– tumors; older
women with HRþ/HER2þ tumors had a mortality rate similar
to older women with HRþ/HER2– tumors. These findings imply
a greater benefit of HER2-targeted treatment (32, 33) on sur-
vival in the younger population, who are more likely to be
HER2-positive and receive targeted treatment (34). In fact, the
most pronounced difference in mortality by age was shown for
patients with HRþ/HER2þ breast cancer, where older patients
had approximately 40% increased risk of breast cancer death
relative to younger patients. It is possible that HRþ/HER2þ
older patients are more likely to forego chemotherapy given the
emerging, but understudied, use of dual antiestrogen/anti-
HER2 therapy. Conversely, a higher risk of mortality regardless
of age group was found for patients with HR–/HER2þ tumors
compared with HRþ/HER2– subtype. The results suggest that
older women might be sacrificing some potential gain in breast
cancer survival to take into account factors such as treatment-
related toxicity, functional status, and other quality of life
measures. Due to the population-based registry nature of our
study, we are unable to assess to what degree these types of
trade-offs are being made by the patient or provider.
Table 3. Breast cancer–specific MRRs comparing older with younger age at
diagnosis by decade and dichotomized at age 50, California, 2005–2014
Age group
Number of deaths
due to breast cancer MRR (95% CI)a MRR (95% CI)b
18–39 723 1.70 (1.56–1.86) 1.20 (1.10–1.32)
40–49 1,513 Referent Referent
50–59 1,929 0.95 (0.88–1.01) 1.06 (0.99–1.14)
60–69 1,584 0.83 (0.77–0.89) 1.12 (1.04–1.21)
70–79 1,317 1.09 (1.02–1.18) 1.56 (1.43–1.69)
80þ 1,403 2.41 (2.24–2.59) 3.25 (2.98–3.55)
18–49 2,236 Referent Referent
50þ 6,233 0.94 (0.90–0.99) 1.17 (1.11–1.23)
aAdjusted for year of diagnosis.
bStratified by AJCC stage, and adjusted for year of diagnosis, marital status,
race/ethnicity, insurance status, neighborhood SES, lymph node involvement,
tumor subtype, tumor size, tumor grade, tumor histology, guideline-concordant
treatment, NCICC, and clustering by block group.
Table 4. Breast cancer–specific MRRs stratified by age at diagnosis, California, 2005–2014
Younger (18–49) Older (50þ)
Number of deaths
due to breast cancer MRR (95% CI)a MRR (95% CI)b
Number of deaths
due to breast cancer MRR (95% CI)a MRR (95% CI)b
All 2,236 6,233
Tumor subtype
HRþ/HER2– 820 Reference Reference 2,781 Reference Reference
HRþ/HER2þ 236 1.11 (0.96–1.29) 0.80 (0.69–0.93) 598 1.69 (1.55–1.85) 1.05 (0.95–1.15)
HR–/HER2þ 214 2.45 (2.11–2.85 1.37 (1.15–1.62) 476 2.86 (2.60–3.16) 1.28 (1.14–1.43)
Triple negative 738 3.88 (3.51–4.29) 2.50 (2.19–2.86) 1,518 4.26 (4.00–4.54) 2.35 (2.17–2.53)
Unclassified 228 1.29 (1.11–1.49) 1.11 (0.96–1.29) 860 1.56 (1.44–1.68) 1.25 (1.16–1.36)
P interaction ¼ 0.0008c
NCICC
No 1,901 Reference Reference 5,784 Reference Reference
Yes 335 1.08 (0.96–1.22) 1.00 (0.89–1.13) 449 0.94 (0.86–1.04) 0.84 (0.76–0.93)
P interaction ¼ 0.003c
Guideline-concordant treatment
Yes 1,409 Reference Reference 2,879 Reference Reference
No 230 1.25 (1.09–1.44) 1.20 (1.03–1.40) 657 1.47 (1.35–1.60) 1.49 (1.36–1.63)
Not available 590 0.32 (0.29–0.36) 1.00 (0.88–1.15) 2,683 0.31 (0.29–0.32) 1.14 (1.05–1.24)
Unknown 7 0.95 (0.45–2.00) 0.59 (0.27–1.30) 14 1.09 (0.65–1.85) 0.79 (0.45–1.40)
P interaction ¼ 0.015c
aAdjusted for year at diagnosis.
bStratified by AJCC stage, and adjusted for year of diagnosis, age at diagnosis (continuous), marital status, race/ethnicity, insurance status, nSES, lymph node
involvement, tumor size, tumor grade, tumor histology, and clustering by block group.
cP for interaction between age group (younger and older) and tumor subtype, NCICC, or guideline-concordant treatment (excluding unknown) from amodel which
included all significant interactions with age group.
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It has been reported in the literature that older patients with
breast cancer receive less guideline-appropriate treatment than
their younger counterparts (8, 35, 36). Therefore, our finding of a
highermortality in older than younger patients inwomenwhodo
not receive guideline-appropriate treatment but not in those who
receive guideline-concordant treatment is noteworthy.Our results
also show that the higher mortality associated with older com-
pared with younger patients is present among women who were
not ever seen at anNCICC and not in patients who received care at
an NCICC. As improved breast cancer treatment guideline con-
cordance and surgical outcomes at an NCICC were reported
previously (37–39), ourfindings imply that for older breast cancer
patients, which represent the vast majority of the patient popu-
lation (80%), receiving care at an NCICC and ensuring that
guideline-appropriate treatment is provided will decrease breast
cancer mortality in this older age group. Although we could not
completely characterize these effects nor do our data allow us to
definitively attribute treatment to specific facilities, the better
survival outcome for older patients may be due to improved
multidisciplinary care coordination, in addition to access to
tumor boards, patient-centered care programs, and clinical trials
for special geriatric cancer care that may be more achievable in
NCICC than in other types of facilities (40, 41). With limited
evidence from clinical trials and research studies on older patients
due to their comorbid conditions or belief from providers that
older patients are incapable of tolerating treatment or have
limited long-term benefit, it is difficult to formulate evidence-
based treatment and guideline-compliance recommendations.
Our study used CCR data from the most recent decade to
examine variation in breast cancer survival in the younger and
older groups. Few previous studies have looked concurrently at
the age cohorts or have included in the analysis tumor subtypes
and receipt of guideline treatment. As the ER, PR, and HER2
designations are becoming increasingly useful in guiding clinical
treatment and in breast cancer research (14, 42), however, our
conclusions need further validation, as subtypes determined by
receptor status serve only as a proxy for full genetic profiling. Also,
our survival analyseswere adjusted for sociodemographic, clinical
characteristics, and first course of cancer-directed treatment,
which are available in the cancer registry. However, our study is
limited by the lack of data on genetic profile, unmeasured treat-
ment information such as dosing or specific regimens, as well as
comorbidities. Consequently, our findings could be subject to
residual confounding from incomplete treatment and comorbid-
ity data in the cancer registry (43), which may be especially
relevant when comparing older and younger patients. We encour-
age further population-based studies with more detailed treat-
ment and clinical data and individual-level measures of socio-
economic factors to explore the mechanisms associated with age-
specific mortality differences.
In summary, our results based onmultivariable-adjusted mod-
els show that women age 50 years and older at diagnosis with
stage I to III breast cancer have a higher risk of dying from breast
cancer compared with younger women, but variation in risk by
age exists according to tumor subtype. In addition, the higher
mortality rate among older relative to younger women was
diminished in women who received guideline-concordant treat-
ment and reversed for patients receiving care at an NCICC,
suggesting that ensuring receipt of appropriate treatment and
patient-centered care provided in NCICCs may help to reduce
age-related differences in breast cancer mortality.
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MRR (95% CI)a Older vs.
younger (referent)
MRR (95% CI)b Older vs.
younger (referent)
Tumor subtype
HRþ/HER2– 820 2,781 1.00 (0.93–1.08) 1.24 (1.14–1.35)
HRþ/HER2þ 236 598 1.34 (1.15–1.56) 1.38 (1.17–1.62)
HR–/HER2þ 214 476 0.97 (0.82–1.14) 0.94 (0.79–1.12)
Triple negative 738 1,518 0.95 (0.87–1.04) 1.01 (0.92–1.11)
Unclassified 228 860 1.16 (1.00–1.34) 1.31 (1.12–1.53)
NCICC
No 1,901 5,784 0.97 (0.92–1.02) 1.21 (1.15–1.28)
Yes 335 449 0.74 (0.64–0.85) 0.86 (0.73–1.01)
Guideline-concordant treatment
Yes 1,409 2,879 1.04 (0.94–1.10) 1.06 (0.99–1.14)
No 230 657 1.18 (1.02–1.37) 1.20 (1.02–1.41)
Not available 590 2,683 1.21 (1.11–1.33) 1.34 (1.22–1.47)
aAdjusted for year of diagnosis.
bStratified by AJCC stage and adjusted for year of diagnosis, marital status, race/ethnicity, insurance status, nSES, lymph node involvement, tumor subtype (in
models not stratified by this), tumor size, tumor grade, tumor histology, guideline-concordant treatment (in models not stratified by this), NCICC (in models not
stratified by this), and clustering by block group.
Tao et al.
Cancer Epidemiol Biomarkers Prev; 28(2) February 2019 Cancer Epidemiology, Biomarkers & Prevention308
on March 9, 2021. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst October 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0353 
Acknowledgments
We would like to thank Valesca Largaespada for her contribution in prep-
aration of the article.
This work was supported by the Specialized Cancer Center Support Grant
to the University of California San Diego Moores Cancer Center (CA023100-
29 to R. Schwab, M. Gago-Dominguez, J. Murphy, A. Molinolo, and
M.E. Martinez) and by the SDSU/UCSD Comprehensive Cancer Center
Partnership (CA132379 and CA132384 to Y. San Miguel and M.E. Martinez).
The collection of cancer incidence data used in this study was supported by
the California Department of Public Health pursuant to California Health
and Safety Code Section 103885; CDC's National Program of Cancer
Registries, under cooperative agreement 5NU58DP006344; the NCI's SEER
Program under contract HHSN261201800032I awarded to the University of
California, San Francisco, contract HHSN261201800015I awarded to the
University of Southern California, and contract HHSN261201800009I
awarded to the Public Health Institute, Cancer Registry of Greater California.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
Received April 4, 2018; revised August 8, 2018; accepted October 10, 2018;
published first October 17, 2018.
References
1. Zilliacus EM, Meiser B, Lobb EA, Kirk J, Warwick L, Tucker K. Women's
experience of telehealth cancer genetic counseling. J Genet Couns
2010;19:463–72.
2. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of
ClinicalOncology policy statement update: genetic and genomic testing for
cancer susceptibility. J Clin Oncol 2010;28:893–901.
3. Kothari AS, Beechey-Newman N, D'Arrigo C, Hanby AM, Ryder K, Hamed
H, et al. Breast carcinoma in women age 25 years or less. Cancer 2002;
94:606–14.
4. XiongQ, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients
with breast carcinoma age 30 years and younger have a poor prognosis: the
M.D. Anderson Cancer Center experience. Cancer 2001;92:2523–8.
5. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H.
Breast cancer in young women: poor survival despite intensive treatment.
PloS One 2009;4:e7695.
6. MaggardMA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young
breast cancer patients have worse outcomes? J Surg Res 2003;113:109–13.
7. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA.
Elevated breast cancer mortality in women younger than age 40 years
compared with older women is attributed to poorer survival in early-stage
disease. J Am College Surg 2009;208:341–7.
8. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P,
et al. Undertreatment strongly decreases prognosis of breast cancer in
elderly women. J Clin Oncol 2003;21:3580–7.
9. Kim J, Durden E. Socioeconomic status and age trajectories of health.
Soc Sci Med 2007;65:2489–502.
10. DanneferD.Cumulative advantage/disadvantage and the life course: cross-
fertilizing age and social science theory. J Gerontol B Psychol Sci Soc Sci
2003;58:S327–37.
11. Bernardi D, Errante D, Tirelli U, Salvagno L, Bianco A, Fentiman IS. Insight
into the treatment of cancer in older patients: developments in the last
decade. Cancer Treat Rev 2006;32:277–88.
12. Siu AL U.S. Preventative Services Task Force. Screening for breast
cancer: U.S. Preventive Services Task Force Recommendation
Statement. Ann Intern Med 2016;164:279–96.
13. MorabiaA,CostanzaMC. International variability in ages atmenarche,first
livebirth, and menopause. World Health Organization Collaborative
Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1998;148:
1195–205.
14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer
Study. JAMA 2006;295:2492–502.
15. Yost K, Perkins C, Cohen R,Morris C,WrightW. Socioeconomic status and
breast cancer incidence in California for different race/ethnic groups.
Cancer Causes Control 2001;12:703–11.
16. Yang J, Schupp CW, Harrati A, Clarke C, Keegan THM, Gomez SL.
Developing an area-based socioeconomic measure from American
Community Survey data. Fremont, CA: Cancer Prevention Institute of
California; 2014.
17. Tao L, Chu L, Wang LI, Moy L, Brammer M, Song C, et al. Occurrence and
outcome of de novo metastatic breast cancer by subtype in a large, diverse
population. Cancer Causes Control 2016;27:1127–38.
18. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis
of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative,
and HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California Cancer Registry.
Cancer 2007;109:1721–8.
19. Bernstein L, Lacey JV Jr.Receptors, associations, and risk factor differences
by breast cancer subtypes: positive or negative? J Natl Cancer Inst 2011;
103:451–3.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ,
et al. American Society of Clinical Oncology/College of American Pathol-
ogists guideline recommendations for human epidermal growth factor
receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
21. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.
Molecular portraits of human breast tumours. Nature 2000;406:747–52.
22. Elledge RM,ClarkGM,ChamnessGC,Osborne CK. Tumor biologic factors
and breast cancer prognosis among white, Hispanic, and black women in
the United States. J Nat Cancer Inst 1994;86:705–12.
23. Kurian AW, Lichtensztajn DY, Keegan TH, Leung RW, Shema SJ, Hershman
DL, et al. Patterns and predictors of breast cancer chemotherapy use in
Kaiser Permanente Northern California, 2004–2007. Breast Cancer Res
Treat 2013;137:247–60.
24. Blayney DW, McNiff K, Hanauer D, Miela G, Markstrom D, Neuss M.
Implementation of the Quality Oncology Practice Initiative at a university
comprehensive cancer center. J Clin Oncol 2009;27:3802–7.
25. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment,
and survival by race and ethnicity. Arch Int Med 2003;163:49–56.
26. Zabicki K, Colbert JA, Dominguez FJ, GaddMA, Hughes KS, Jones JL, et al.
Breast cancer diagnosis inwomen<or¼40versus 50 to60 years: increasing
size and stage disparity compared with older women over time. Ann Surg
Oncol 2006;13:1072–7.
27. Keegan TH, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, et al.
Impact of breast cancer subtypes on 3-year survival among adolescent and
young adult women. Breast Cancer Res 2013;15:R95.
28. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG,
Pruneri G, et al. Prognosis and adjuvant treatment effects in selected breast
cancer subtypes of very young women (<35 years) with operable breast
cancer. Ann Oncol 2010;21:1974–81.
29. Azim HA Jr., Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis
M, et al. Elucidating prognosis and biology of breast cancer arising in
young women using gene expression profiling. Clin Cancer Res
2012;18:1341–51.
30. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW,
et al. Race and triple negative threats to breast cancer survival: a
population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;
113:357–70.
31. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al.
Intrinsic breast tumor subtypes, race, and long-term survival in the Car-
olina Breast Cancer Study. Clin Cancer Res 2010;16:6100–10.
32. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus
trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med
2012;366:109–19.
33. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant
breast cancer trials. Semin Oncol 2001;28:13–9.
34. Anderson WF, Katki HA, Rosenberg PS. Incidence of breast cancer in the
United States: current and future trends. J Natl Cancer Inst 2011;103:
1397–402.
35. Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, et al. Patterns
of chemotherapy, toxicity, and short-term outcomes for older women
Breast Cancer Mortality in Older and Younger Patients
www.aacrjournals.org Cancer Epidemiol Biomarkers Prev; 28(2) February 2019 309
on March 9, 2021. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst October 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0353 
receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat
2014;145:491–501.
36. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA,
Crawford J, et al. Social and racial differences in selection of breast
cancer adjuvant chemotherapy regimens. J Clin Oncol 2007;25:
2522–7.
37. Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD. Do cancer
centers designated by the National Cancer Institute have better surgical
outcomes? Cancer 2005;103:435–41.
38. Friese CR, Earle CC, Silber JH, Aiken LH. Hospital characteristics, clinical
severity, and outcomes for surgical oncology patients. Surgery 2010;147:
602–9.
39. InH,Neville BA, Lipsitz SR, Corso KA,Weeks JC, Greenberg CC. The role of
National Cancer Institute-designated cancer center status: observed vari-
ation in surgical care depends on the level of evidence. Ann Surg
2012;255:890–5.
40. ArchampongD, Borowski D,Wille-Jorgensen P, Iversen LH.Workload and
surgeon's specialty for outcome after colorectal cancer surgery. Cochrane
Database Syst Rev 2012:CD005391.
41. Chapman AE, Swartz K, Schoppe J, Arenson C. Development of a com-
prehensive multidisciplinary geriatric oncology center, the Thomas Jeffer-
son University experience. J Geriatr Oncol 2014;5:164–70.
42. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB,
et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr
Canc Netw 2009;7:122–92.
43. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS.
Limits of observational data in determining outcomes from cancer therapy.
Cancer 2008;112:2456–66.
Cancer Epidemiol Biomarkers Prev; 28(2) February 2019 Cancer Epidemiology, Biomarkers & Prevention310
Tao et al.
on March 9, 2021. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst October 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0353 
2019;28:303-310. Published OnlineFirst October 17, 2018.Cancer Epidemiol Biomarkers Prev 
  
Li Tao, Richard B. Schwab, Yazmin San Miguel, et al. 
  


































Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cebp.aacrjournals.org/content/28/2/303
To request permission to re-use all or part of this article, use this link
on March 9, 2021. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Published OnlineFirst October 17, 2018; DOI: 10.1158/1055-9965.EPI-18-0353 
